로딩 중…
지수 로딩 중…
SK Bioscience Co.,Ltd
302440· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩38,650-1.90%
2026-06-19
Price Chart
SK Bioscience Co.,Ltd-14.21%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 3.03T KRW |
| Revenue | 665.42B KRW |
| Net Income | -86.66B KRW |
| Total Assets | 2.99T KRW |
| Net Assets | 2.02T KRW |
| Employees | 1,021 |
| Value | |
| P/B | 1.50x |
| P/S | 4.56x |
| FCF Yield | -2.66% |
| Profitability | |
| ROE | -4.28% |
| ROA | -2.90% |
| Op. Margin | -22.98% |
| Revenue Growth | 9.09% |
| Financial Health | |
| Debt Ratio | 147.85% |
| Total Debt | 1.07T KRW |
| FCF | -80.58B KRW |
| Cash | 86.72B KRW |
| Current Ratio | 4.04x |
| Performance | |
| 1Y Return | -14.21% |
| 1M Return | -3.86% |
| From 52W High | -36.95% |
| 1Y MDD | -37.85% |
| Trading | |
| Volume | 216,844 shares |
| Foreign Own. | 5.43% |
| Per Share | |
| EPS | -1,062 KRW |
| BPS | 22,571 KRW |
Company Info
SK Bioscience was established in 2018 through a spin-off of SK Chemical's vaccine business division, officially entering the global market in 2024 with the acquisition of a German CDMO specialized company. Its core businesses are vaccine/biopharmaceutical research and development, production, sales, and CDMO, with revenue composed of 18.4% proprietary vaccines, 7.6% product sales, and 74.0% CDMO. The company develops disease prevention and treatment pharmaceuticals using diverse vaccine production technologies. SK Bioscience is executing a strategy to grow into a Global Top 10 Vaccine Company and is headquartered in Seongnam-si, Gyeonggi-do.